LT2975042T - Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui - Google Patents

Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui

Info

Publication number: LT2975042T
Authority: LT; Lithuania
Prior art keywords: inhibition; tyrosine kinase; kinase activity; pyrimidine derivatives; fused pyrimidine
Prior art date: 2010-06-23

Application number

LTEP15181011.6T

Other languages

English (en)

Inventor

Mi Young Cha

Seok Jong Kang

Mi Ra Kim

Ju Yeon Lee

Ji Young Jeon

Myoung Gi Jo

Eun Joo Kwak

Kwang Ok Lee

Tae Hee Ha

Kwee Hyun Suh

Maeng Sup Kim

Original Assignee

Hanmi Science Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-23

Filing date

2011-06-20

Publication date

2019-01-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45371929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2975042(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-06-20 Application filed by Hanmi Science Co., Ltd. filed Critical Hanmi Science Co., Ltd.

2019-01-25 Publication of LT2975042T publication Critical patent/LT2975042T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3834—Aromatic acids (P-C aromatic linkage)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)

LTEP15181011.6T 2010-06-23 2011-06-20 Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui LT2975042T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
KR20100059686		2010-06-23

Publications (1)

Publication Number	Publication Date
LT2975042T true LT2975042T (lt)	2019-01-25

Family

ID=45371929

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
LTEP15181011.6T LT2975042T (lt)	2010-06-23	2011-06-20	Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui
LTEP11798350.2T LT2585470T (lt)	2010-06-23	2011-06-20	Nauji kondensuoti pirimidino dariniai tirozino kinazės aktyvumo slopinimui

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
LTEP11798350.2T LT2585470T (lt)	2010-06-23	2011-06-20	Nauji kondensuoti pirimidino dariniai tirozino kinazės aktyvumo slopinimui

Country Status (31)

Country	Link
US (4)	USRE46511E1 (lt)
EP (2)	EP2975042B1 (lt)
JP (2)	JP5834347B2 (lt)
KR (2)	KR101587506B1 (lt)
CN (2)	CN102947316B (lt)
AR (2)	AR081978A1 (lt)
AU (1)	AU2011269989B2 (lt)
BR (2)	BR112012033253A2 (lt)
CA (1)	CA2803056C (lt)
CY (1)	CY1118750T1 (lt)
DK (2)	DK2585470T3 (lt)
ES (2)	ES2703552T3 (lt)
HR (2)	HRP20170456T1 (lt)
HU (2)	HUE042165T2 (lt)
IL (2)	IL223689A (lt)
LT (2)	LT2975042T (lt)
MX (2)	MX342164B (lt)
MY (2)	MY162132A (lt)
NZ (2)	NZ627709A (lt)
PH (1)	PH12012502431B1 (lt)
PL (2)	PL2975042T3 (lt)
PT (2)	PT2975042T (lt)
RS (2)	RS58265B1 (lt)
RU (2)	RU2585177C2 (lt)
SG (1)	SG186378A1 (lt)
SI (2)	SI2585470T1 (lt)
TR (1)	TR201821217T4 (lt)
TW (2)	TWI528962B (lt)
UA (2)	UA108889C2 (lt)
WO (1)	WO2011162515A2 (lt)
ZA (1)	ZA201209742B (lt)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2526934B1 (en)	2006-09-22	2015-12-09	Pharmacyclics LLC	Inhibitors of bruton's tyrosine kinase
US20120101113A1 (en)	2007-03-28	2012-04-26	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
BRPI0908637B8 (pt)	2008-05-21	2021-05-25	Ariad Pharma Inc	composto e composição farmacêutica do mesmo
ES2660418T3 (es)	2008-07-16	2018-03-22	Pharmacyclics Llc	Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
CA3240281A1 (en)	2010-06-03	2011-12-08	Pharmacyclics Llc	Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of follicular lymphoma
BR112012033253A2 (pt) *	2010-06-23	2016-11-22	Hanmi Science Co Ltd	novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase
PE20140245A1 (es)	2010-10-08	2014-03-30	Abbvie Inc	Compuesto de furo[3,2-d]pirimidina
JP2013539795A (ja) *	2010-10-14	2013-10-28	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖の阻害方法
EP2704572B1 (en) *	2011-05-04	2015-12-30	Ariad Pharmaceuticals, Inc.	Compounds for inhibiting cell proliferation in egfr-driven cancers
JP2014520863A (ja)	2011-07-13	2014-08-25	ファーマサイクリックス，インク．	Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤
LT3333161T (lt)	2011-07-27	2020-05-11	Astrazeneca Ab	2-(2,4,5-pakeistieji-anilino)pirimidino dariniai kaip egfr moduliatoriai, naudingi vėžio gydymui
KR20130076046A (ko) *	2011-12-28	2013-07-08	한미약품 주식회사	타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
US8377946B1 (en)	2011-12-30	2013-02-19	Pharmacyclics, Inc.	Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9464089B2 (en)	2012-01-13	2016-10-11	Acea Biosciences Inc.	Heterocyclic compounds and uses thereof
US9586965B2 (en)	2012-01-13	2017-03-07	Acea Biosciences Inc.	Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
JP6353788B2 (ja)	2012-01-13	2018-07-04	エイシアバイオサイエンシーズインコーポレイテッド	抗がん剤としての複素環式化合物およびその使用
US9034885B2 (en)	2012-01-13	2015-05-19	Acea Biosciences Inc.	EGFR modulators and uses thereof
KR20130091464A (ko) *	2012-02-08	2013-08-19	한미약품 주식회사	타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
JP5557963B2 (ja) *	2012-02-23	2014-07-23	大鵬薬品工業株式会社	キノリルピロロピリミジル縮合環化合物又はその塩
US20150166591A1 (en) *	2012-05-05	2015-06-18	Ariad Pharmaceuticals, Inc.	Methods and compositions for raf kinase mediated diseases
NZ713828A (en)	2012-06-04	2017-05-26	Pharmacyclics Llc	Crystalline forms of a bruton’s tyrosine kinase inhibitor
WO2013184766A1 (en) *	2012-06-06	2013-12-12	Irm Llc	Compounds and compositions for modulating egfr activity
MX2015001081A (es)	2012-07-24	2015-10-14	Pharmacyclics Inc	Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
CA2890934A1 (en)	2012-11-15	2014-05-22	Pharmacyclics, Inc.	Pyrrolopyrimidine compounds as kinase inhibitors
KR20150119401A (ko)	2013-02-22	2015-10-23	다이호야쿠힌고교 가부시키가이샤	3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
CN103242341B (zh) *	2013-04-19	2015-12-09	中国科学院广州生物医药与健康研究院	噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
WO2014175370A1 (ja) *	2013-04-25	2014-10-30	塩野義製薬株式会社	ピロリジン誘導体およびそれらを含有する医薬組成物
AU2014256633B2 (en)	2013-04-25	2017-02-02	Beone Medicines I Gmbh	Fused heterocyclic compounds as protein kinase inhibitors
CN117486865A (zh)	2013-07-11	2024-02-02	艾森医药公司	嘧啶衍生物作为激酶抑制剂
CA2919996A1 (en)	2013-08-02	2015-02-05	Pharmacyclics Llc	Methods for the treatment of solid tumors
EP2832358A1 (en)	2013-08-02	2015-02-04	Bionsil S.r.l.	Pharmaceutical kit for use in the treatment of colon and colorectal cancer
US9415050B2 (en)	2013-08-12	2016-08-16	Pharmacyclics Llc	Methods for the treatment of HER2 amplified cancer
WO2015035606A1 (en)	2013-09-13	2015-03-19	Beigene, Ltd.	Anti-pd1 antibodies and their use as therapeutics and diagnostics
MX368781B (es) *	2013-09-18	2019-10-16	Beijing Hanmi Pharmaceutical Co Ltd	Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
PE20160560A1 (es)	2013-09-30	2016-06-09	Pharmacyclics Llc	DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDIN COMO INHIBIDORES IRREVERSIBLES DE LA TIROSINA CINASA DE BRUTON (BTK)
FR3015483B1 (fr) *	2013-12-23	2016-01-01	Servier Lab	Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2942528A1 (en)	2014-03-20	2015-09-24	Pharmacyclics Inc.	Phospholipase c gamma 2 and resistance associated mutations
WO2015148904A1 (en) *	2014-03-28	2015-10-01	Driver Group	Methods for predicting egfr tyrosine kinase inhibitor efficacy
KR102359214B1 (ko)	2014-04-04	2022-02-07	델 마 파마슈티컬스	폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
SG11201608299TA (en)	2014-05-01	2016-11-29	Novartis Ag	Compounds and compositions as toll-like receptor 7 agonists
ES2877050T3 (es)	2014-05-01	2021-11-16	Novartis Ag	Compuestos y composiciones como agonistas del receptor 7 de tipo toll
JPWO2015182628A1 (ja) *	2014-05-28	2017-04-20	アステラス製薬株式会社	ピラジンカルボキサミド化合物を有効成分とする医薬組成物
CN106604742B (zh)	2014-07-03	2019-01-11	百济神州有限公司	抗pd-l1抗体及其作为治疗剂及诊断剂的用途
EP2974729A1 (en) *	2014-07-17	2016-01-20	Abivax	Quinoline derivatives for use in the treatment of inflammatory diseases
AU2015296215A1 (en)	2014-08-01	2017-03-23	Pharmacyclics Llc	Inhibitors of bruton's tyrosine kinase
RU2017106795A (ru)	2014-08-07	2018-09-07	Фармасайкликс Элэлси	Новые составы ингибитора тирозинкиназы брутона
AR101476A1 (es)	2014-08-07	2016-12-21	Acerta Pharma Bv	Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
CN107108649B (zh) *	2014-12-30	2019-08-09	韩美药品株式会社	用于制备噻吩并嘧啶化合物的新型方法及其中使用的中间体
KR20160082062A (ko)	2014-12-30	2016-07-08	한미약품 주식회사	싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체
CN105837572B (zh) *	2015-02-02	2019-04-19	四川大学	N-取代苯基酰胺衍生物及其制备方法和用途
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
RU2572709C1 (ru) *	2015-03-03	2016-01-20	Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации	Способ коррекции структурно-функциональных нарушений артериального русла у больных ревматоидным артритом
EP3290419B1 (en)	2015-04-29	2019-08-07	Guangdong Zhongsheng Pharmaceutical Co., Ltd	Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor
CA2992161A1 (en)	2015-07-17	2017-01-26	Institut Pasteur	5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
MA44909A (fr)	2015-09-15	2018-07-25	Acerta Pharma Bv	Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
WO2017059702A1 (en)	2015-10-09	2017-04-13	Acea Biosciences, Inc	Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
MA44334A (fr)	2015-10-29	2018-09-05	Novartis Ag	Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
KR20170050453A (ko) *	2015-10-30	2017-05-11	한미약품 주식회사	싸이에노피리미딘 화합물의 신규 제조방법 및 이에 사용되는 중간체
CN108137614B (zh) *	2015-12-02	2021-01-05	深圳市塔吉瑞生物医药有限公司	一种稠合嘧啶化合物及包含该化合物的组合物及其用途
JP6978003B2 (ja) *	2015-12-03	2021-12-08	チョーチアンチアンフェン−イエンバイオテクノロジーカンパニーリミテッド	複素環式化合物およびその使用
EP3383401B1 (en) *	2015-12-03	2020-05-20	Zheijiang Jianfreng-Yien Biotechnology Co., Ltd.	Thieno-pyrimidine derivatives and uses thereof
BR112018013356A2 (pt) *	2015-12-31	2018-12-04	Hanmi Pharm Ind Co Ltd	sal de cloridrato, formas cristalinas de um sal de cloridrato e composição farmacêutica
HK1252842A1 (zh) *	2015-12-31	2019-06-06	韩美药品株式会社	噻吩并嘧啶化合物的结晶形式
WO2017122175A1 (en)	2016-01-13	2017-07-20	Acerta Pharma B.V.	Therapeutic combinations of an antifolate and a btk inhibitor
EP3458064A1 (en) *	2016-05-18	2019-03-27	Boehringer Ingelheim International GmbH	Anticancer combination therapy
WO2017204582A1 (en) *	2016-05-27	2017-11-30	Hanmi Pharm. Co., Ltd.	Pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof inhibiting growth of cancer cells and a stabilizer having low melting point
BR112018074621B1 (pt)	2016-06-30	2021-06-08	Daewoong Pharmaceutical Co., Ltd	compostos derivados de pirazolopirimidina como inibidores de quinase, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
JP6993056B2 (ja)	2016-07-05	2022-02-15	ベイジーンリミテッド	癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
EP3484462B1 (en)	2016-07-15	2022-12-14	Institut Pasteur	5-hydroxytryptamine 1b receptor-stimulating agent for skin and/or hair repair
CN107698603B (zh)	2016-08-09	2022-04-08	南京红云生物科技有限公司	噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
EP4353322A3 (en)	2016-08-16	2024-07-31	BeiGene Switzerland GmbH	Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
US11701357B2 (en)	2016-08-19	2023-07-18	Beigene Switzerland Gmbh	Treatment of B cell cancers using a combination comprising Btk inhibitors
MA46285A (fr)	2016-09-19	2019-07-31	Mei Pharma Inc	Polythérapie
CN106565612B (zh) *	2016-10-25	2018-10-16	大连医科大学	二苯乙烯基嘧啶类化合物，组合物及其用途
US11590167B2 (en)	2016-12-03	2023-02-28	Juno Therapeutic, Inc.	Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
KR20180075228A (ko)	2016-12-26	2018-07-04	한미약품 주식회사	싸이에노피리미딘 화합물의 신규 제조방법 및 중간체
US20190376971A1 (en)	2017-01-19	2019-12-12	Acerta Pharma B.V.	Compositions and Methods for the Assessment of Drug Target Occupancy for Bruton's Tyrosine Kinase
TWI774726B (zh)	2017-01-25	2022-08-21	英屬開曼群島商百濟神州有限公司	(S)-7-(1-(丁-2-炔醯基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氫吡唑并[1,5-a]嘧啶-3-甲醯胺的晶型、及其製備和用途
WO2018139883A1 (ko) *	2017-01-26	2018-08-02	부광약품 주식회사	다중 표적 키나아제 저해제로서 융합피리미딘 유도체
CN106831814B (zh) *	2017-02-15	2018-11-23	山东大学	一种噻吩并[3,2-d]嘧啶类HIV-1逆转录酶抑制剂及其制备方法和应用
CN106916112B (zh) *	2017-03-02	2019-12-20	四川海思科制药有限公司	嘧啶衍生物及其制备方法和在医药上的应用
CN106866699B (zh) *	2017-03-29	2019-03-08	山东大学	一种二芳基噻吩并嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用
EP3606925A1 (en)	2017-04-07	2020-02-12	ACEA Therapeutics, Inc.	Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN108727382B (zh) *	2017-04-19	2022-07-19	华东理工大学	作为btk抑制剂的杂环化合物及其应用
TWI877099B (zh)	2017-06-26	2025-03-21	英屬開曼群島商百濟神州有限公司	抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途
CN109206435B (zh) *	2017-06-29	2020-09-08	中国医药研究开发中心有限公司	噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
WO2019034009A1 (en)	2017-08-12	2019-02-21	Beigene, Ltd.	BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
US20200172529A1 (en) *	2017-08-18	2020-06-04	Beijing Hanmi Pharm. Co., Ltd.	Chemical Compound, Pharmaceutical Composition Thereof, and Use and Application Thereof
CN109575045B (zh) *	2017-09-28	2021-02-12	南京红云生物科技有限公司	噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
KR102613433B1 (ko) *	2017-10-11	2023-12-13	주식회사 대웅제약	신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
BR112020009361A2 (pt)	2017-11-17	2020-10-13	Cellix Bio Private Limited	composto de fórmula i, composição farmacêutica para tratar um distúrbio ocular ou complicações do mesmo, método de síntese de composto, método de tratamento de um distúrbio ocular ou complicações do mesmo em um indivíduo que precisa do mesmo e uso de um composto
CN111801334B (zh)	2017-11-29	2023-06-09	百济神州瑞士有限责任公司	使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
JP7043098B2 (ja) *	2017-12-21	2022-03-29	深▲チェン▼市塔吉瑞生物医薬有限公司	キナーゼ活性を阻害するためのジアニリノピリミジン系化合物
PE20201146A1 (es) *	2017-12-28	2020-10-26	Dae Woong Pharma	Derivado de oxi-fluoropiperidina como inhibidor de quinasa
KR102577241B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko) *	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
MY206796A (en) *	2018-04-23	2025-01-08	Celgene Corp	Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma
EP3789040A4 (en)	2018-04-27	2022-03-09	ONO Pharmaceutical Co., Ltd.	PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT
JOP20210017A1 (ar)	2018-07-25	2021-01-21	Novartis Ag	مثبطات جسيم التهابي nlrp3
KR101954370B1 (ko)	2018-07-25	2019-03-05	한미약품 주식회사	피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
WO2020043321A1 (en)	2018-08-31	2020-03-05	Stichting Katholieke Universiteit	Synergistic combinations of amino acid depletion agent sensitizers (aadas) and amino acid depletion agents (aada), and therapeutic methods of use thereof
CN109265469A (zh) *	2018-11-12	2019-01-25	大连医科大学附属第医院	嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途
EP3669873A1 (en)	2018-12-20	2020-06-24	Abivax	Quinoline derivatives for use ine the traeatment of inflammation diseases
MX2021010115A (es)	2019-02-22	2021-09-21	Hanmi Pharm Ind Co Ltd	Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.
CN111747950B (zh) *	2019-03-29	2024-01-23	深圳福沃药业有限公司	用于治疗癌症的嘧啶衍生物
US12465608B2 (en)	2019-03-29	2025-11-11	Astrazeneca Ab	Osimertinib for use in the treatment of non-small cell lung cancer
KR102819183B1 (ko) *	2019-03-29	2025-06-13	한미약품 주식회사	퓨로피리미딘 화합물의 산 부가염의 결정형
CN111909101B (zh) *	2019-05-10	2022-07-19	浙江大学	一种egfr激酶抑制剂及其在制备抗癌药物方面的应用
UY38687A (es)	2019-05-17	2023-05-15	Novartis Ag	Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
CA3133004A1 (en)	2019-05-31	2020-12-03	Sichuan Haisco Pharmaceutical Co., Ltd.	Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
TW202446397A (zh)	2019-06-10	2024-12-01	瑞士商百濟神州瑞士有限責任公司	一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法
WO2020257385A1 (en) *	2019-06-20	2020-12-24	Dana-Farber Cancer Institute, Inc.	Small molecule inhibitors of src tyrosine kinase
CA3144228A1 (en) *	2019-06-25	2020-12-30	Sinopsee Therapeutics	Compounds for treatment of eye disorders
JP2022538817A (ja)	2019-06-27	2022-09-06	ハンミファーマシューティカルカンパニーリミテッド	Ｆｌｔ３阻害剤および化学療法剤を含む急性骨髄白血病を治療するための薬学的組成物
CN110372529B (zh) *	2019-08-08	2022-05-24	黄河水利职业技术学院	N-[(3,4,5-三氟)苯基]丙烯酰胺及其制备方法
CN110511994B (zh) *	2019-09-09	2023-05-26	中南大学湘雅二医院	miRNA-4769-3p及其同源物的应用
CN114761013A (zh)	2019-09-27	2022-07-15	迪斯克医药公司	治疗骨髓纤维化和相关病症的方法
EP4048666A1 (en) *	2019-10-21	2022-08-31	Celgene Corporation	Solid forms comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and salts thereof, and compositions comprising the same and their use
MX2022007518A (es) *	2019-12-20	2022-09-19	Pfizer	Derivados bencimidazol.
KR20230012539A (ko)	2020-05-13	2023-01-26	디스크 메디슨, 인크.	골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
EP4161656A4 (en)	2020-06-05	2024-06-19	Kinnate Biopharma Inc.	Inhibitors of fibroblast growth factor receptor kinases
CN111732597B (zh) *	2020-06-20	2022-11-01	江西科技师范大学	含4-酰胺苯氧基的2-氨基嘧啶杂环类化合物的制备及应用
PE20230855A1 (es)	2020-08-14	2023-05-29	Novartis Ag	Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmaceuticos de los mismos
CA3197034A1 (en) *	2020-10-29	2022-05-05	Suzhou Yabao Pharmaceutical R&D Co., Ltd.	Substituted diarylamine compound, pharmaceutical composition thereof, preparation method therefor, and use thereof
US20240216330A1 (en)	2021-04-02	2024-07-04	Biogen Ma Inc.	Combination treatment methods of multiple sclerosis
US11786531B1 (en)	2022-06-08	2023-10-17	Beigene Switzerland Gmbh	Methods of treating B-cell proliferative disorder
UY40374A (es)	2022-08-03	2024-02-15	Novartis Ag	Inhibidores de inflamasoma nlrp3
WO2024123126A1 (ko) *	2022-12-09	2024-06-13	재단법인대구경북과학기술원	올무티닙을 유효성분으로 포함하는 신경염증 또는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP970371A2 (en) *	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
CN1835923A (zh) *	2003-08-19	2006-09-20	惠氏控股公司	制备4－氨基－3－喹啉腈的方法
US8440663B2 (en)	2006-01-30	2013-05-14	Exelixis, Inc.	4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use
JP2008013527A (ja) *	2006-07-10	2008-01-24	Sankyo Co Ltd	チエノ［３，２−ｄ］ピリミジン−２，４−ジアミン誘導体
RU2470936C2 (ru)	2006-12-07	2012-12-27	Дженентек, Инк.	Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения
WO2008152394A1 (en) *	2007-06-12	2008-12-18	F.Hoffmann-La Roche Ag	Pharmaceutical compounds
WO2009017838A2 (en)	2007-08-01	2009-02-05	Exelixis, Inc.	Combinations of jak-2 inhibitors and other agents
AU2008323628B2 (en) *	2007-11-15	2013-10-17	Ym Biosciences Australia Pty Ltd	N-containing heterocyclic compounds
CA2720946C (en) *	2008-04-07	2013-05-28	Irm Llc	Compounds and compositions as protein kinase inhibitors
MX382352B (es) *	2008-06-27	2025-03-13	Celgene Car Llc	Compuestos de heteroarilo y usos de los mismos.
TWI385174B (zh) *	2008-11-10	2013-02-11	Nat Health Research Institutes	作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物
ES2659725T3 (es) *	2009-05-05	2018-03-19	Dana-Farber Cancer Institute, Inc.	Inhibidores de EGFR y procedimiento de tratamiento de trastornos
US20110207736A1 (en)	2009-12-23	2011-08-25	Gatekeeper Pharmaceuticals, Inc.	Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
BR112012033253A2 (pt) *	2010-06-23	2016-11-22	Hanmi Science Co Ltd	novos derivados de pirimidina fundidos para inibição da atividade de tirosina quinase
EP2758402B9 (en) *	2011-09-22	2016-09-14	Pfizer Inc	Pyrrolopyrimidine and purine derivatives

2011
- 2011-06-20 BR BR112012033253A patent/BR112012033253A2/pt not_active IP Right Cessation
- 2011-06-20 DK DK11798350.2T patent/DK2585470T3/en active
- 2011-06-20 HU HUE15181011A patent/HUE042165T2/hu unknown
- 2011-06-20 ES ES15181011T patent/ES2703552T3/es active Active
- 2011-06-20 RS RS20190004A patent/RS58265B1/sr unknown
- 2011-06-20 PL PL15181011T patent/PL2975042T3/pl unknown
- 2011-06-20 US US15/099,171 patent/USRE46511E1/en active Active
- 2011-06-20 SI SI201131094A patent/SI2585470T1/sl unknown
- 2011-06-20 LT LTEP15181011.6T patent/LT2975042T/lt unknown
- 2011-06-20 EP EP15181011.6A patent/EP2975042B1/en active Active
- 2011-06-20 HR HRP20170456TT patent/HRP20170456T1/hr unknown
- 2011-06-20 PT PT15181011T patent/PT2975042T/pt unknown
- 2011-06-20 CN CN201180030338.6A patent/CN102947316B/zh active Active
- 2011-06-20 RU RU2013102881/04A patent/RU2585177C2/ru not_active IP Right Cessation
- 2011-06-20 EP EP11798350.2A patent/EP2585470B1/en active Active
- 2011-06-20 JP JP2013516501A patent/JP5834347B2/ja active Active
- 2011-06-20 CN CN201510477438.3A patent/CN105061438B/zh active Active
- 2011-06-20 ES ES11798350.2T patent/ES2622138T3/es active Active
- 2011-06-20 DK DK15181011.6T patent/DK2975042T3/en active
- 2011-06-20 PL PL11798350T patent/PL2585470T3/pl unknown
- 2011-06-20 TR TR2018/21217T patent/TR201821217T4/tr unknown
- 2011-06-20 AU AU2011269989A patent/AU2011269989B2/en not_active Ceased
- 2011-06-20 LT LTEP11798350.2T patent/LT2585470T/lt unknown
- 2011-06-20 NZ NZ627709A patent/NZ627709A/en unknown
- 2011-06-20 UA UAA201300777A patent/UA108889C2/uk unknown
- 2011-06-20 WO PCT/KR2011/004482 patent/WO2011162515A2/en not_active Ceased
- 2011-06-20 US US13/805,183 patent/US8957065B2/en not_active Ceased
- 2011-06-20 MX MX2014005025A patent/MX342164B/es unknown
- 2011-06-20 PT PT117983502T patent/PT2585470T/pt unknown
- 2011-06-20 HU HUE11798350A patent/HUE032515T2/en unknown
- 2011-06-20 NZ NZ605988A patent/NZ605988A/en not_active IP Right Cessation
- 2011-06-20 RU RU2014147193/04A patent/RU2598852C2/ru active
- 2011-06-20 BR BR122014012788-0A patent/BR122014012788B1/pt active IP Right Grant
- 2011-06-20 CA CA2803056A patent/CA2803056C/en active Active
- 2011-06-20 SI SI201131644T patent/SI2975042T1/sl unknown
- 2011-06-20 MX MX2012014601A patent/MX2012014601A/es active IP Right Grant
- 2011-06-20 SG SG2012092862A patent/SG186378A1/en unknown
- 2011-06-20 KR KR1020110059612A patent/KR101587506B1/ko active Active
- 2011-06-20 UA UAA201410791A patent/UA111272C2/uk unknown
- 2011-06-20 RS RS20170267A patent/RS55783B1/sr unknown
- 2011-06-20 PH PH1/2012/502431A patent/PH12012502431B1/en unknown
- 2011-06-20 MY MYPI2012005536A patent/MY162132A/en unknown
- 2011-06-22 TW TW100121796A patent/TWI528962B/zh not_active IP Right Cessation
- 2011-06-22 TW TW103121058A patent/TWI513701B/zh active
- 2011-06-23 AR ARP110102172A patent/AR081978A1/es unknown
2012
- 2012-12-17 IL IL223689A patent/IL223689A/en active IP Right Grant
- 2012-12-20 MY MYPI2016002018A patent/MY174196A/en unknown
- 2012-12-21 ZA ZA2012/09742A patent/ZA201209742B/en unknown
2014
- 2014-04-09 KR KR1020140042459A patent/KR101589114B1/ko active Active
- 2014-04-23 AR ARP140101695A patent/AR096075A2/es active IP Right Grant
- 2014-04-30 IL IL232382A patent/IL232382A/en active IP Right Grant
- 2014-05-13 JP JP2014099471A patent/JP5852173B2/ja active Active
- 2014-10-23 US US14/521,766 patent/US9345719B2/en active Active
2016
- 2016-04-15 US US15/099,815 patent/US20160229868A1/en not_active Abandoned
2017
- 2017-03-20 CY CY20171100349T patent/CY1118750T1/el unknown
2019
- 2019-01-03 HR HRP20190012TT patent/HRP20190012T1/hr unknown

Also Published As

Publication number	Publication date
ZA201209742B (en)	2014-03-26
NZ605988A (en)	2014-11-28
AU2011269989B2 (en)	2014-12-11
USRE46511E1 (en)	2017-08-15
MX342164B (es)	2016-09-19
PT2585470T (pt)	2017-03-06
EP2975042B1 (en)	2018-10-03
EP2975042A1 (en)	2016-01-20
SI2975042T1 (sl)	2019-02-28
CN105061438A (zh)	2015-11-18
LT2585470T (lt)	2017-04-10
RU2013102881A (ru)	2014-07-27
JP5852173B2 (ja)	2016-02-03
IL232382A (en)	2016-12-29
RU2014147193A (ru)	2015-07-10
TW201204364A (en)	2012-02-01
ES2703552T3 (es)	2019-03-11
WO2011162515A2 (en)	2011-12-29
KR20140060473A (ko)	2014-05-20
US20160229868A1 (en)	2016-08-11
CA2803056C (en)	2017-05-16
RU2585177C2 (ru)	2016-05-27
RS58265B1 (sr)	2019-03-29
TR201821217T4 (tr)	2019-01-21
SI2585470T1 (sl)	2017-03-31
BR112012033253A2 (pt)	2016-11-22
CN102947316A (zh)	2013-02-27
TW201443059A (zh)	2014-11-16
AU2011269989A8 (en)	2013-02-28
NZ627709A (en)	2014-12-24
AU2011269989A1 (en)	2013-02-07
RS55783B1 (sr)	2017-07-31
MY174196A (en)	2020-03-13
WO2011162515A3 (en)	2012-05-03
MY162132A (en)	2017-05-31
US20130116213A1 (en)	2013-05-09
HRP20190012T1 (hr)	2019-02-22
KR20110139653A (ko)	2011-12-29
HUE042165T2 (hu)	2019-06-28
IL232382A0 (en)	2014-06-30
AR081978A1 (es)	2012-10-31
JP5834347B2 (ja)	2015-12-16
PH12012502431A1 (en)	2013-07-08
EP2585470A2 (en)	2013-05-01
AR096075A2 (es)	2015-12-02
HRP20170456T1 (hr)	2017-05-19
TWI513701B (zh)	2015-12-21
PH12012502431B1 (en)	2019-08-23
IL223689A (en)	2017-03-30
MX2012014601A (es)	2013-02-21
KR101587506B1 (ko)	2016-01-25
CA2803056A1 (en)	2011-12-29
CN102947316B (zh)	2016-08-10
US9345719B2 (en)	2016-05-24
DK2585470T3 (en)	2017-04-10
DK2975042T3 (en)	2019-01-21
CN105061438B (zh)	2017-07-04
BR122014012788A2 (pt)	2019-08-13
TWI528962B (zh)	2016-04-11
US8957065B2 (en)	2015-02-17
PT2975042T (pt)	2019-01-11
BR122014012788B1 (pt)	2022-04-19
UA111272C2 (uk)	2016-04-11
EP2585470A4 (en)	2014-01-01
HK1211575A1 (en)	2016-05-27
JP2013529630A (ja)	2013-07-22
US20150045324A1 (en)	2015-02-12
SG186378A1 (en)	2013-01-30
RU2598852C2 (ru)	2016-09-27
CY1118750T1 (el)	2017-07-12
UA108889C2 (uk)	2015-06-25
ES2622138T3 (es)	2017-07-05
EP2585470B1 (en)	2017-01-25
KR101589114B1 (ko)	2016-01-29
HUE032515T2 (en)	2017-09-28
JP2014159473A (ja)	2014-09-04
PL2585470T3 (pl)	2017-07-31
PL2975042T3 (pl)	2019-07-31

Publication	Publication Date	Title
HRP20190012T1 (hr)	2019-02-22	Novi fuzionirani pirimidin derivati za inhibiciju aktivnosti tirozin kinaze
IL213906A0 (en)	2011-07-31	Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
ZA201407441B (en)	2022-05-25	Solid forms of an epidermal growth factor receptor kinase inhibitor
EP2593462A4 (en)	2014-07-09	NEW CONDENSED HETEROCYCLIC DERIVATIVES SUITABLE AS C-MET TYROSINE KINASE HEMMER
ZA201309702B (en)	2015-01-28	Inhibitors of lrrk2 kinase activity
IL220155B (en)	2019-05-30	History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors
ZA201303614B (en)	2014-11-26	Quinazolin-4(3h)-one derivatives used as p13 kinase inhibitors
ZA201201703B (en)	2014-05-28	Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
SG2014009260A (en)	2014-09-26	Aminopyrimidine derivatives for use as modulators of kinase activity
ZA201201978B (en)	2013-12-23	Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
ZA201402549B (en)	2015-08-26	Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
ZA201500471B (en)	2016-10-26	Crystalline form i of tyrosine kinase inhibitor dimaleate and preparation methods thereof
IL218790A0 (en)	2012-06-28	Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
ZA201207482B (en)	2013-09-25	Inhibitors of protein tyrosine kinase activity
EP2754659A4 (en)	2015-08-26	4-SUBSTITUTED- (3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO) -PYRIMIDINES DERIVATIVES HAVING PROTEIN KINASE INHIBITION ACTIVITY AND USE THEREOF
AU2013201520B9 (en)	2016-03-10	Solid forms of an epidermal growth factor receptor kinase inhibitor
IL244032B (en)	2018-03-29	Intermediates for the preparation of pyrazolylquinoxaline kinase inhibitors